Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Findling

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Wiener Medizinische Wochenschrift (1946)|June 20, 2022
An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumabArkady Ovchinnikov, Oliver Findling
Drug Discovery Today|November 28, 2020
Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?Oliver Findling, Johann Sellner
Journal of Neurology|June 14, 2014
Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysisThomas Hundsberger, Kai M Rösler, Oliver Findling
Journal of Neuromuscular Diseases|November 19, 2016
Long-Term Interruption of Enzyme Replacement Therapy with rhGAA in Pompe Disease Leads to Irreversible Clinical DeclineThomas Hundsberger, Kai M Rösler, Oliver Findling
Acta Neurologica Belgica|April 18, 2008
Tumefactive lesion in multiple sclerosisOliver Findling, Johann Sellner, Christoph Ozdoba, et al.
Multiple Sclerosis and Related Disorders|December 22, 2022
Oral disease modifying therapies - A game changer for treatment decision in untreated patients with RRMS and CIS? - A swiss single center cross-sectional studySebastian Finkener, Lutz Achtnichts, Michaela Cervenakova, et al.
Therapeutic Advances in Neurological Disorders|August 18, 2018
Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimodLara Diem, Krassen Nedeltchev, Timo Kahles, et al.
Journal of Clinical Medicine|January 30, 2020
Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of ImmunotherapiesOliver Findling, Larissa Hauer, Thomas Pezawas, et al.
Journal of Neurology|September 21, 2018
36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe RegistryOlivier Scheidegger, Daniela Leupold, Rafael Sauter, et al.
The Lancet. Neurology|May 19, 2009
EAYNT: promoting training in neuro-rehabilitationWalter Struhal, Barbara Hess, Laszlo Sztriha, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Wiener Medizinische Wochenschrift (1946)|June 20, 2022
An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumabArkady Ovchinnikov, Oliver Findling
Drug Discovery Today|November 28, 2020
Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?Oliver Findling, Johann Sellner
Journal of Neurology|June 14, 2014
Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysisThomas Hundsberger, Kai M Rösler, Oliver Findling
Journal of Neuromuscular Diseases|November 19, 2016
Long-Term Interruption of Enzyme Replacement Therapy with rhGAA in Pompe Disease Leads to Irreversible Clinical DeclineThomas Hundsberger, Kai M Rösler, Oliver Findling
Acta Neurologica Belgica|April 18, 2008
Tumefactive lesion in multiple sclerosisOliver Findling, Johann Sellner, Christoph Ozdoba, et al.
Multiple Sclerosis and Related Disorders|December 22, 2022
Oral disease modifying therapies - A game changer for treatment decision in untreated patients with RRMS and CIS? - A swiss single center cross-sectional studySebastian Finkener, Lutz Achtnichts, Michaela Cervenakova, et al.
Therapeutic Advances in Neurological Disorders|August 18, 2018
Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimodLara Diem, Krassen Nedeltchev, Timo Kahles, et al.
Journal of Clinical Medicine|January 30, 2020
Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of ImmunotherapiesOliver Findling, Larissa Hauer, Thomas Pezawas, et al.
Journal of Neurology|September 21, 2018
36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe RegistryOlivier Scheidegger, Daniela Leupold, Rafael Sauter, et al.
The Lancet. Neurology|May 19, 2009
EAYNT: promoting training in neuro-rehabilitationWalter Struhal, Barbara Hess, Laszlo Sztriha, et al.
Pageof 6